Basak Ecem Bircan

Basak Ecem Bircan

Auto-generated profile, based on publicly available information

Basak Ecem Bircan

Division of Endocrinology and Metabolism, Department of Internal Medicine, İstanbul University-Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2022 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
MGMustafa Sait Gönen
Mustafa Sait Gönen
ABAnnamaria De Bellis
Annamaria De Bellis
EDEmre Durcan
Emre Durcan
GBGiuseppe Bellastella
Giuseppe Bellastella
PCPaolo Cirillo
Paolo Cirillo
FKFahrettin Kelestimur
Fahrettin Kelestimur
SARS-CoV-2 may affect the hypothalamic-pituitary axis and pituitary dysfunction may occur. Therefore, we investigated neuroendocrine changes, in particular, secondary adrenal insufficiency, using a dynamic test and the role of autoimmunity in pituitary dysfunction in patients with COVID-19. The single-center, prospective, case-control study included patients with polymerase chain reaction (PCR)-confirmed COVID-19 and healthy controls. Basal hormone levels were measured, and the adrenocorticotropic hormone (ACTH) stimulation test was performed. Antipituitary (APA) and antihypothalamic antibodies (AHA) were also determined. We examined a total of 49 patients with COVID-19 and 28 healthy controls. The frequency of adrenal insufficiency in patients with COVID-19 was found as 8.2%. Patients with COVID-19 had lower free T3, IGF-1, and total testosterone levels, and higher cortisol and prolactin levels when compared with controls. We also demonstrated the presence of APA in three and AHA in one of four patients with adrenal insufficiency. In conclusion, COVID-19 may result in adrenal insufficiency, thus routine screening of adrenal functions in these patients is needed. Endocrine disturbances in COVID-19 are similar to those seen in acute stressful conditions or infections. Pituitary or hypothalamic autoimmunity may play a role in neuroendocrine abnormalities in COVID-19. Received: 21 November 2021 Accepted after revision: 27 January 2022 Publication Date: 11 March 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

21 November 2021 in Journal of Sex & Marital Therapy
Verified
Journal Article
Closed access
EDEmre Durcan
Emre Durcan
ŞTŞenol Turan
Şenol Turan
BBBasak Ecem Bircan
Basak Ecem Bircan
SYSelver Yaylamaz
Selver Yaylamaz
ODOznur Demirel
Oznur Demirel
PKPınar Kadıoğlu
Pınar Kadıoğlu
Based on the possible effects of androgens on the course of COVID-19, it can be posited that Gender-Affirming Hormone Therapy (GAHT) may affect the course of the disease in people with GD. We aimed to investigate the relationship between GAHT and contracting COVID-19, as well as the severity of the disease in individuals with Gender Dysphoria (GD). The single center, cross-sectional, web-based survey was completed by people with GD who received GAHT. The questionnaire contained three parts: a sociodemographic data form; a GAHT data form; a COVID-19-related data form. Of the 238 participants, 179 were individuals with female-to-male (FtM) and 59 male-to-female (MtF) GD. We detected that the risk of contracting COVID-19 increased 3.46 times in people with FtM GD, who had received testosterone therapy, in comparison to people with MtF GD, who received estrogen and anti-androgen therapy. Additionally, people with FtM GD who contracted COVID-19 had received longer testosterone therapy when compared to those who did not contract COVID-19. Our findings indicate that individuals with FtM GD who receive testosterone treatment within the scope of GAHT are at higher risk of contracting COVID-19 and that the clinicians who follow-up on GAHT should be more careful about this issue.

8 September 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
PDF file
GDGizem Durcan
Gizem Durcan
EDEmre Durcan
Emre Durcan
ŞTŞenol Turan
Şenol Turan
SYSelver Yaylamaz
Selver Yaylamaz
BBBaşak Ecem Bircan
Başak Ecem Bircan
PKPınar Kadıoğlu
Pınar Kadıoğlu
Objective: This study aimed to evaluate the effect of gender-affirming hormone therapy (GAHT) on social functioning in individuals with female-to-male (FtM) gender dysphoria (GD) and to examine the roles of social support, bilateral mastectomy, and real-life experience. Methods: This cross-sectional study included 77 individuals with FtM GD, 41 of whom were receiving GAHT. The Social Functioning Scale (SFS) was used to evaluate participants’ social functioning. Data on family support, partner status, history of bilateral mastectomy, and duration of real-life experience were collected. Results: Individuals receiving GAHT had higher overall social functioning, particularly in social engagement, interpersonal behavior, and pro-social activities, respectively (P = .01, P = .001, P = .002, P = .027). There were no significant differences in the recreation, independence–competence, independence–performance, and employment/occupation subscales (for all P > .05). Family support was associated with better social functioning across several domains, whereas having a partner was linked to improvements in specific areas. Participants who had undergone bilateral mastectomy also demonstrated higher social functioning scores. In addition, longer real-life experience was positively associated with overall social functioning, pro-social activities, and recreation. Conclusion: Gender-affirming hormone therapy is associated with improved social functioning in individuals with FtM GD, especially in interpersonal domains. Bilateral mastectomy, social support, and real-life experience also appear to contribute to better social adaptation. These findings highlight the combined role of medical interventions and supportive social environments in shaping social functioning. Cite this article as: Durcan G, Durcan E, Turan Ş, et al. Social Functioning in female-to-male Individuals: gender-affirming care and social supports. Cerrahpaşa Med J 2026, 50, 0071, doi: 10.5152/cjm.2026.26071.